Pesquisar
Agenus Inc
AGENAdicionar à lista de desejos
3.580USD
0.0000.00%
Fechamento 05/15, 16:00（ET）Cotações atrasadas em 15 min
149.08MValor de mercado
1.73P/L TTM
Mais detalhes de Agenus Inc Empresa
Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Informações de Agenus Inc
Código da empresaAGEN
Nome da EmpresaAgenus Inc
Data de listagemFeb 04, 2000
CEOArmen (Garo H)
Número de funcionários316
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 04
Endereço3 Forbes Rd
CidadeLEXINGTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02421-7305
Telefone17816744400
Sitehttps://agenusbio.com/
Código da empresaAGEN
Data de listagemFeb 04, 2000
CEOArmen (Garo H)
Executivos da empresa Agenus Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Thomas L. (Tom) Harrison, Ph.D.
Mr. Thomas L. (Tom) Harrison, Ph.D.
Independent Director
Independent Director
39.00K
+23.66%
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Vice President - Finance
Vice President - Finance
23.48K
+67.22%
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
4.60K
--
Wright (Timothy R)
Wright (Timothy R)
Lead Independent Director
Lead Independent Director
2.77K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Jennifer S. Buell, Ph.D.
Dr. Jennifer S. Buell, Ph.D.
Director
Director
--
--
Ms. Susan F. Hirsch
Ms. Susan F. Hirsch
Independent Director
Independent Director
--
--
Dr. Steven O'Day, M.D.
Dr. Steven O'Day, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Richard Goldberg
Mr. Richard Goldberg
Chief Development Officer
Chief Development Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Thomas L. (Tom) Harrison, Ph.D.
Mr. Thomas L. (Tom) Harrison, Ph.D.
Independent Director
Independent Director
39.00K
+23.66%
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Vice President - Finance
Vice President - Finance
23.48K
+67.22%
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
4.60K
--
Wright (Timothy R)
Wright (Timothy R)
Lead Independent Director
Lead Independent Director
2.77K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Jennifer S. Buell, Ph.D.
Dr. Jennifer S. Buell, Ph.D.
Director
Director
--
--
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de abr
Moeda: USDAtualizado em: seg, 6 de abr
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por EmpresaUSD
Nome
Receita
Proporção
Non-cash royalty revenue
108.59M
95.09%
Pre-commercial product revenue
4.24M
3.71%
Other services
1.04M
0.91%
Clinical product revenue
334.00K
0.29%
Por RegiãoUSD
Nome
Receita
Proporção
United States
113.16M
99.09%
Rest of World
1.04M
0.91%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Non-cash royalty revenue
108.59M
95.09%
Pre-commercial product revenue
4.24M
3.71%
Other services
1.04M
0.91%
Clinical product revenue
334.00K
0.29%
Distribuição de ações
Atualizado em: qua, 13 de mai
Atualizado em: qua, 13 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Zydus Lifesciences Ltd
5.12%
Vanguard Capital Management, LLC
3.46%
Vanguard Portfolio Management, LLC
2.87%
Invus Public Equities Advisors, LLC
2.56%
Renaissance Technologies LLC
1.31%
Outro
84.69%
Investidores
Investidores
Proporção
Zydus Lifesciences Ltd
5.12%
Vanguard Capital Management, LLC
3.46%
Vanguard Portfolio Management, LLC
2.87%
Invus Public Equities Advisors, LLC
2.56%
Renaissance Technologies LLC
1.31%
Outro
84.69%
Tipos de investidores
Investidores
Proporção
Investment Advisor
13.72%
Investment Advisor/Hedge Fund
5.42%
Hedge Fund
5.15%
Corporation
5.14%
Individual Investor
1.56%
Research Firm
1.12%
Pension Fund
0.91%
Outro
66.99%
Participação acionária institucional
Atualizado em: qua, 1 de abr
Atualizado em: qua, 1 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q1
275
10.91M
26.27%
-968.40K
2025Q4
304
9.95M
37.38%
--
2025Q3
332
9.95M
41.39%
+217.92K
2025Q2
334
9.73M
47.54%
+407.61K
2025Q1
334
9.33M
45.75%
-2.82M
2024Q4
341
8.45M
52.98%
-249.79K
2024Q3
351
8.70M
54.68%
-447.45K
2024Q2
347
9.21M
64.12%
-1.91M
2024Q1
356
10.69M
65.28%
-2.98M
2023Q4
374
11.90M
61.88%
+645.94K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Zydus Lifesciences Ltd
2.13M
5.56%
+2.13M
--
Jan 15, 2026
Invus Public Equities Advisors, LLC
1.06M
2.77%
--
--
Dec 31, 2025
Renaissance Technologies LLC
543.55K
1.42%
+477.35K
+721.07%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
485.30K
1.26%
+16.52K
+3.52%
Dec 31, 2025
Citadel Advisors LLC
423.24K
1.1%
+423.24K
--
Dec 31, 2025
Armen (Garo H.)
394.77K
1.03%
+8.98K
+2.33%
Mar 20, 2026
Geode Capital Management, L.L.C.
372.75K
0.97%
+25.76K
+7.42%
Dec 31, 2025
Wellington Management Company, LLP
290.65K
0.76%
--
--
Dec 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0%
iShares Russell 3000 ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Schwab U.S. Small-Cap ETF
0%
SPDR Portfolio MSCI Global Stock Market ETF
0%
Global X Russell 2000 ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
Ver Mais
iShares Micro-Cap ETF
Proporção0.02%
iShares Russell 2000 Growth ETF
Proporção0%
iShares Russell 3000 ETF
Proporção0%
Invesco NASDAQ Future Gen 200 ETF
Proporção0%
Fidelity Enhanced Small Cap ETF
Proporção0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
Schwab U.S. Small-Cap ETF
Proporção0%
SPDR Portfolio MSCI Global Stock Market ETF
Proporção0%
Global X Russell 2000 ETF
Proporção0%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Data
Data ex-dividendo
Tipo
Proporção
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
